GlaxoSmithKline’s share price and 5% dividend yield make it my buy of the decade

Harvey Jones says the combination of a cut price valuation and 5% plus yield make GlaxoSmithKline plc (LON: GSK) a rare opportunity for long-term investors.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceutical giant GlaxoSmithKline (LSE: GSK) has just published its first quarter results, and investors are underwhelmed. The stock is down 2.64% after a mixed set of numbers, made worse by the currency impact of a strengthening sterling. Does that deter me from hailing it my buy of the decade? Certainly not.

Drugs do work

Glaxo delivered sales of £7.2bn across Q1, a rise of 4% at constant exchange rates (CER), but a drop of 2% at actual exchange rates (AER), thanks to the pound getting back its bounce. Sales grew across all three of its businesses, Pharmaceuticals, Consumer Healthcare and Vaccines (the smallest of the three but growing fastest at 13% CER). 

Adjusted operating margins rose 1.3 percentage points to a healthy 26.6% at CER, although down 0.2 points at AER. Total earnings per share (EPS) fell sharply, by as much as 33% at CER and 48% at AER, although the group said this reflects the revaluation of its Consumer Healthcare business following the agreement to acquire full ownership. Adjusted EPS grew 11% at CER, beating estimates, while down 2% at AER.

Free cash flow disappointed, plunging 50% to £324m, reflecting the £317m vaccine sales milestone payment to Novartis.

Cash flows

Glaxo declared a dividend of 19p for the quarter and remains on course to pay out 80p across 2018, for the fifth consecutive year. City analysts are expecting a slight uplift to 80.33p in 2019, but that will depend on the group boosting its free cash flow. Right now, it is prioritising R&D as it looks to extend its drugs pipeline. The current forecast yield of 5.6%, covered 1.3 times, hardly needs beefing up. There are higher yielding FTSE 100 stocks out there, though.

CEO Emma Walmsley said Glaxo continued to make good progress, with CER sales growth across all three businesses. She added: “We are strongly focused on commercial execution with encouraging starts for our most recent new product launches, Shingrix, Trelegy and Juluca.”

Good health

Continued cost discipline helped boost Glaxo’s adjusted operating margin at CER. Meanwhile acquiring full ownership of the Consumer Healthcare business should “improve future cash generation and support capital planning for the Group’s main priority to strengthen the Pharmaceuticals business and R&D pipeline,” Walmsley said.

One of the big issues relates to when generic competition to its blockbuster US treatment Advair emerges. Glaxo reported increased pricing and competitive pressures in the US inhaled respiratory market during Q1, predicting a 30% decline in sales, while a mid-year introduction of a substitutable generic competitor to Advair could knock adjusted EPS to around 3%.

Keep taking the tablets

Glaxo won’t be the only FTSE 100 company punished by sterling’s recovery and if interest rates rise and Brexit negotiations make progress, there could be more to pain on that front. However, I prefer to buy on bad news rather than good.

Walmsley appears to have a tight grip on the business and recent product launches sound positive. You don’t often get the opportunity to buy Glaxo at a forward valuation of just 13.5 times earnings. That is why I reckon that it remains a great buy-and-hold for the next decade and beyond.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Investing Articles

Here’s the worst thing to do in a stock market crash (it isn’t selling)

When the stock market falls sharply – as it does from time to time – selling is often a bad…

Read more »

New year resolutions 2025 on desk. 2025 resolutions list with notebook, coffee cup on table.
Investing Articles

My top 2 growth shares to consider buying in 2025

For investors looking for top growth shares to buy in the New Year, I reckon this pair are well worth…

Read more »

Investing Articles

3 massive UK shares that could relocate their listing in 2025

I've identified three UK companies that may consider moving their share listing abroad next year. What does this mean for…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

2 common mistakes investors make with dividend shares

Stephen Wright outlines two common mistakes to avoid when considering dividend shares. One is about building wealth, the other is…

Read more »

Investing Articles

Here’s how I’ll learn from Warren Buffett to try to boost my 2025 investment returns

Thinking about Warren Buffett helps reassure me about my long-term investing approach. But I definitely need to learn some more.

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

Here are the best (and worst) S&P 500 sectors of 2024

While the S&P 500 has done well as a whole, some sectors have fared better than others. Stephen Wright is…

Read more »

Investing Articles

2 FTSE 100 stocks I think could be takeover targets in 2025

If the UK stock market gets moving in 2025, I wonder if the FTSE 100 might offer a few tasty…

Read more »

Young Asian woman with head in hands at her desk
Growth Shares

Are these areas of the stock market in a bubble as we approach 2025?

Certain areas of the stock market have felt a little frothy in recent weeks. And Edward Sheldon believes that investors…

Read more »